Pairidex Closes Over-Subscribed Seed Round to Support the Launch of New Highly Sensitive MRD Test for Leukemia.
The financing brings in $4.89M in new capital to accelerate the commercial launch of FusionMRD™ ST. LOUIS, MO, UNITED STATES, July 27, 2026 /EINPresswire.com/ -- Pairidex, a precision diagnostics company advancing personalized molecular testing …